Virios Therapeutics

General Information
Business:

 

We are a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (“FM”). Overactive immune response related to activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease (“IBS”), chronic fatigue syndrome and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease. While not completely understood, there is general agreement in the medical community that activation of HSV-1 is triggered by some form of environmental and/or health stressor.

Our lead development candidate (“IMC-1”), is a novel proprietary fixed-dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination antiviral therapy designed to synergistically suppress HSV-1 activation and replication, with the end goal of reducing viral mediated disease burden.

Industry: Pharmaceuticals
Employees: 4
Founded: 2012
Contact Information
Address 44 Milton Avenue Alpharetta, GA 30009
Phone Number (866) 620-8655
Web Address http://www.virios.com
View Prospectus: Virios Therapeutics
Financial Information
Market Cap
Revenues $0 mil (last 12 months)
Net Income $-3.6 mil (last 12 months)
IPO Profile
Symbol VIRI
Exchange NASDAQ
Shares (millions): 3.0
Price range $9.00 - $11.00
Est. $ Volume $30.0 mil
Manager / Joint Managers ThinkEquity (a division of Fordham Financial Management)
CO-Managers
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change